IoM Drug Safety Review Should Reach Beyond FDA, Agency’s Woodcock Says

The scope of the Institute of Medicine's assessment of the U.S. drug safety system must extend beyond an evaluation of FDA's capabilities, FDA Acting Deputy Commissioner for Operations Janet Woodcock said June 8